- Home
- INBK vs AGEN Comparison
INBK vs AGEN Comparison
Compare INBK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INBK | AGEN |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.2M | 126.8M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | INBK | AGEN |
|---|---|---|
| Price | $19.73 | $3.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $28.67 | $14.50 |
| AVG Volume (30 Days) | 86.4K | ★ 510.5K |
| Earning Date | 01-21-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $46,731,000.00 | ★ $106,829,000.00 |
| Revenue This Year | $4.47 | $67.15 |
| Revenue Next Year | $25.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.05 | $1.38 |
| 52 Week High | $42.75 | $7.34 |
Technical Indicators
Market Signals| Indicator | INBK | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 39.98 |
| Support Level | $18.51 | $4.05 |
| Resistance Level | $20.50 | $4.64 |
| Average True Range (ATR) | 0.87 | 0.22 |
| MACD | 0.30 | -0.04 |
| Stochastic Oscillator | 78.84 | 1.39 |
Price Performance
Historical ComparisonAbout INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).